Modes of action of TLR7 agonists in cancer therapy (Q38271879)

1 September 2017

1 reference

title

Modes of action of TLR7 agonists in cancer therapy (English)

1 reference

1 September 2017

0 references

4

Stefan Endres

1 reference

1 September 2017

Sebastian Kobold

1

1 reference

PubMed ID

25428647

1 September 2017

Gabriela Wiedemann

series ordinal

2

1 reference

PubMed ID

25428647

1 September 2017

Simon Rothenfußer

series ordinal

3

1 reference

1 September 2017

1 January 2014

1 reference

1 September 2017

1 reference

1 September 2017

6

1 reference

1 September 2017

10

1 reference

1 September 2017

1085-1095

1 reference

Drosophila Toll and IL-1 receptor

1 September 2017

1 reference

The evolution of vertebrate Toll-like receptors

21 January 2018

1 reference

Trial Watch: Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

21 January 2018

1 reference

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

21 January 2018

1 reference

Toll-like receptors as therapeutic targets for cancer.

21 January 2018

1 reference

Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons

21 January 2018

1 reference

Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial

21 January 2018

1 reference

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

21 January 2018

1 reference

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

21 January 2018

1 reference

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

21 January 2018

1 reference

Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity

21 January 2018

1 reference

Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

21 January 2018

1 reference

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

21 January 2018

1 reference

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines

21 January 2018

1 reference

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

21 January 2018

1 reference

Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.

21 January 2018

1 reference

B Cell-intrinsic TLR7 signaling is required for optimal B cell responses during chronic viral infection

21 January 2018

1 reference

Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

21 January 2018

1 reference

TLR8: the forgotten relative revindicated

21 January 2018

1 reference

Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies

21 January 2018

1 reference

Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8.

21 January 2018

1 reference

Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.

21 January 2018

1 reference

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy

21 January 2018

1 reference

A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition.

21 January 2018

1 reference

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines

21 January 2018

1 reference

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

21 January 2018

1 reference

Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males

21 January 2018

1 reference

TLR7 ligands induce higher IFN-alpha production in females.

21 January 2018

1 reference

The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling.

21 January 2018

1 reference

TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells

21 January 2018

1 reference

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance

21 January 2018

1 reference

Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans

21 January 2018

1 reference

Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder

21 January 2018

1 reference

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod

21 January 2018

1 reference

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

21 January 2018

1 reference

Regulation of TLR7/9 signaling in plasmacytoid dendritic cells

21 January 2018

1 reference

Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages

21 January 2018

1 reference

UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes

21 January 2018

1 reference

Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase.

21 January 2018

1 reference

Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells

21 January 2018

1 reference

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

21 January 2018

1 reference

Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

21 January 2018

1 reference

The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway

21 January 2018

1 reference

The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes

21 January 2018

1 reference

Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity.

21 January 2018

1 reference

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

21 January 2018

1 reference

Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?

21 January 2018

1 reference

Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.

21 January 2018

1 reference

Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

21 January 2018

1 reference

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

21 January 2018

1 reference

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

21 January 2018

1 reference

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment

21 January 2018

1 reference

Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation

21 January 2018

1 reference

Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets

21 January 2018

1 reference

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

21 January 2018

1 reference

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

21 January 2018

1 reference

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation

21 January 2018

1 reference

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity

21 January 2018

1 reference

Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer

21 January 2018

1 reference

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

21 January 2018

1 reference

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

21 January 2018

1 reference

TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity

21 January 2018

1 reference

Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.

21 January 2018

1 reference

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination

21 January 2018

1 reference

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

21 January 2018

1 reference

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

21 January 2018

1 reference

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients

21 January 2018

1 reference

Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin

21 January 2018

1 reference

Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.

21 January 2018

1 reference

Immunomodulation by imiquimod in patients with high-risk primary melanoma

21 January 2018

1 reference

Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors

21 January 2018

1 reference

Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response.

21 January 2018

1 reference

Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells

21 January 2018

1 reference

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients

21 January 2018

1 reference

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy

21 January 2018

1 reference

The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

21 January 2018

1 reference

A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin

21 January 2018

1 reference

Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells

21 January 2018

1 reference

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection

21 January 2018

1 reference

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

21 January 2018

1 reference

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

21 January 2018

1 reference

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

21 January 2018

1 reference

Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop

21 January 2018

1 reference

Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents

21 January 2018

1 reference

Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells

21 January 2018

1 reference

Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

21 January 2018

1 reference

Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells

21 January 2018

1 reference

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

21 January 2018

1 reference

Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer

21 January 2018

1 reference

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

21 January 2018

1 reference

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

21 January 2018

1 reference

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

21 January 2018

1 reference

Type I IFN Receptor and the B Cell Antigen Receptor Regulate TLR7 Responses via Distinct Molecular Mechanisms

21 January 2018

1 reference

Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.75

1 reference

1 September 2017

1 reference

PubMed ID

25428647